| Wirkstoffe | Handelsname | Hersteller |
|---|---|---|
| Nukleosidische Reverse-Transkriptase-Inhibitoren (NRTI) und Festkombinationen mit NRTI | ||
| Abacavir | Ziagen | ViiV Healthcare |
| Abacavir/Lamivudin | Abacavir/Lamivudin Ratiopharm | Ratiopharm |
| Abacavir/Lamivudin 1 | Kivexa | ViiV Healthcare |
| Abacavir/Lamivudin/Dolutegravir 1 | Triumeq | ViiV Healthcare |
| Abacavir/Lamivudin/Zidovudin 1 | Trizivir | ViiV Healthcare |
| Cobicistat 2 | Tybost | Gilead |
| Didanosin | Videx | Bristol-Myers Squibb |
| Emtricitabin | Emtriva | Gilead |
| Lamivudin | Epivir | ViiV Healthcare |
| Lamivudin/Zidovudin 1 | Combivir | ViiV Healthcare |
| Stavudin | Zerit | Bristol-Myers Squibb |
| Tenofovir | Viread | Gilead |
| Tenofovir/Emtricitabin 1 | Descovy | Gilead |
| Tenofovir/Emtricitabin 1 | Truvada | Gilead |
| Tenofovir/Emtricitabin/Efavirenz 1 | Atripla | Gilead Bristol-Myers Squibb |
| Tenofovir/Emtricitabin/Elvitegravir/Cobicistat 1 | Genvoya | Gilead |
| Tenofovir/Emtricitabin/Elvitegravir/Cobicistat 1 | Stribild | Gilead |
| Tenofovir/Emtricitabin/Rilpivirin 1 | Eviplera | Gilead |
| Tenofovir/Emtricitabin/Rilpivirin 1 | Odefsey | Gilead |
| Zidovudin | Retrovir | ViiV Healthcare |
| Nicht-nukleosidische Reverse-Transkriptase-Inhibitoren (NNRTI) | ||
| Efavirenz | Sustiva | Bristol-Myers Squibb |
| Etravirin | Intelence | Janssen-Cilag |
| Nevirapin | Viramune | Boehringer Ingelheim |
| Rilpivirin | Edurant | Janssen-Cilag |
| Integrase-Inhibitoren | ||
| Dolutegravir | Tivicay | ViiV Healthcare |
| Raltegravir | Isentress | MSD Sharp & Dohme |
| Protease-Inhibitoren | ||
| Atazanavir | Reyataz | Bristol-Myers Squibb |
| Darunavir | Prezista | Janssen-Cilag |
| Fosamprenavir | Telzir | ViiV Healthcare |
| Indinavir | Crixivan | MSD Sharp & Dohme |
| Lopinavir | Kaletra | AbbVie |
| Nelfinavir | Viracept | Hoffmann-La Roche |
| Ritonavir 2 | Norvir | AbbVie |
| Saquinavir | Invirase | Hoffmann La-Roche |
| Tipranavir | Aptivus | Boehringer Ingelheim |
| Entry-Inhibitoren | ||
| Enfuvirtid | Fuzeon | Hoffmann-La Roche |
| Maraviroc | Celsentri | ViiV Healthcare |
Tabelle 2: Liste der aktuell verfügbaren Therapeutika zum Einsatz gegen das HI-Virus. Quelle: Rote Liste
1 Festkombination, 2 Wirkstoffverstärker